Suppr超能文献

通过反义技术视角揭示分枝杆菌杀菌作用的奥秘

Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense.

作者信息

Kaur Parvinder, Datta Santanu, Shandil Radha Krishan, Kumar Naveen, Robert Nanduri, Sokhi Upneet K, Guptha Supreeth, Narayanan Shridhar, Anbarasu Anand, Ramaiah Sudha

机构信息

Research Area, Drug Discovery, AstraZeneca India Private Limited, Bangalore, India.

Drug Discovery, Bugworks, C-CAMP, Bangalore, India.

出版信息

PLoS One. 2016 May 4;11(5):e0154513. doi: 10.1371/journal.pone.0154513. eCollection 2016.

Abstract

One of the major impediments in anti-tubercular drug discovery is the lack of a robust grammar that governs the in-vitro to the in-vivo translation of efficacy. Mycobacterium tuberculosis (Mtb) is capable of growing both extracellular as well as intracellular; encountering various hostile conditions like acidic milieu, free radicals, starvation, oxygen deprivation, and immune effector mechanisms. Unique survival strategies of Mtb have prompted researchers to develop in-vitro equivalents to simulate in-vivo physiologies and exploited to find efficacious inhibitors against various phenotypes. Conventionally, the inhibitors are screened on Mtb under the conditions that are unrelated to the in-vivo disease environments. The present study was aimed to (1). Investigate cidality of Mtb targets using a non-chemical inhibitor antisense-RNA (AS-RNA) under in-vivo simulated in-vitro conditions.(2). Confirm the cidality of the targets under in-vivo in experimental tuberculosis. (3). Correlate in-vitro vs. in-vivo cidality data to identify the in-vitro condition that best predicts in-vivo cidality potential of the targets. Using cidality as a metric for efficacy, and AS-RNA as a target-specific inhibitor, we delineated the cidality potential of five target genes under six different physiological conditions (replicating, hypoxia, low pH, nutrient starvation, nitrogen depletion, and nitric oxide).In-vitro cidality confirmed in experimental tuberculosis in BALB/c mice using the AS-RNA allowed us to identify cidal targets in the rank order of rpoB>aroK>ppk>rpoC>ilvB. RpoB was used as the cidality control. In-vitro and in-vivo studies feature aroK (encoding shikimate kinase) as an in-vivo mycobactericidal target suitable for anti-TB drug discovery. In-vitro to in-vivo cidality correlations suggested the low pH (R = 0.9856) in-vitro model as best predictor of in-vivo cidality; however, similar correlation studies in pathologically relevant (Kramnik) mice are warranted. In the acute infection phase for the high fidelity translation, the compound efficacy may also be evaluated in the low pH, in addition to the standard replication condition.

摘要

抗结核药物研发的主要障碍之一是缺乏一种强大的规则来指导从体外药效到体内药效的转化。结核分枝杆菌(Mtb)既能在细胞外生长,也能在细胞内生长;会遇到各种不利条件,如酸性环境、自由基、饥饿、缺氧和免疫效应机制。Mtb独特的生存策略促使研究人员开发体外模型来模拟体内生理过程,并利用这些模型寻找针对各种表型的有效抑制剂。传统上,抑制剂是在与体内疾病环境无关的条件下对Mtb进行筛选的。本研究旨在:(1)在体外模拟体内条件下,使用非化学抑制剂反义RNA(AS-RNA)研究Mtb靶点的杀菌活性。(2)在实验性结核病的体内条件下确认靶点的杀菌活性。(3)关联体外和体内杀菌活性数据,以确定最能预测靶点体内杀菌潜力的体外条件。以杀菌活性作为药效指标,以AS-RNA作为靶点特异性抑制剂,我们在六种不同生理条件(复制、缺氧、低pH、营养饥饿、氮耗竭和一氧化氮)下描绘了五个靶基因的杀菌潜力。使用AS-RNA在BALB/c小鼠的实验性结核病中确认的体外杀菌活性,使我们能够按rpoB>aroK>ppk>rpoC>ilvB的顺序确定杀菌靶点。RpoB用作杀菌对照。体外和体内研究表明,aroK(编码莽草酸激酶)是适合抗结核药物研发的体内杀分枝杆菌靶点。体外到体内的杀菌活性相关性表明,低pH体外模型(R = 0.9856)是体内杀菌活性的最佳预测指标;然而,有必要在病理相关(Kramnik)小鼠中进行类似的相关性研究。在急性感染期进行高保真翻译时,除了标准的复制条件外,还可以在低pH条件下评估化合物的药效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbcb/4856384/6295c205e2c8/pone.0154513.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验